2269 — WuXi Biologics (Cayman) Balance Sheet
0.000.00%
Last trade - 00:00
- HK$57.42bn
- HK$54.18bn
- CNY17.03bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 6,748 | 8,481 | 11,126 | 8,714 | 11,243 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,773 | 3,122 | 4,851 | 6,126 | 6,820 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 9,672 | 14,204 | 19,530 | 18,470 | 21,198 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 6,796 | 12,870 | 19,756 | 25,916 | 29,939 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 17,602 | 28,964 | 44,033 | 49,564 | 56,576 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,871 | 4,498 | 8,256 | 9,319 | 7,636 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 4,818 | 8,399 | 11,754 | 14,517 | 16,244 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 12,784 | 20,564 | 32,279 | 35,047 | 40,332 |
Total Liabilities & Shareholders' Equity | 17,602 | 28,964 | 44,033 | 49,564 | 56,576 |
Total Common Shares Outstanding |